The cost of gastrointestinal cancer care in older adults is high, and hospital readmission after major GI cancer surgery can be particularly costly. The Center for Medicare Services (CMS) estimates that around 75% of these readmissions are preventable. For these patients, early warning signs for dehydration, infection, or other complications, if noted earlier, would allow physicians to intervene and prevent readmission. Dr.

Prostate cancer is a clinically variable disease – some patients do well, while others do very poorly – and recent studies have shown clear molecular subtypes of prostate cancer that may explain this variability. Some subtypes of prostate cancer have underlying defects in repairing their DNA, making them potentially sensitive to therapies that exploit this deficiency. Dr. Barbieri [MetLife Foundation Clinical Investigator] is a surgeon scientist whose overall goal is to translate our understanding of the molecular basis of prostate cancer into near term benefits for patients.